                               SEQUENCE LISTING

<110> JANSSEN PHARMACEUTICA NV

<120> ANTIBODIES TO RISPERIDONE AND USE THEREOF

<130> 18668-409072 (PRD3397WOPCT)

<140>
<141>

<150> 62/268,898
<151> 2015-12-17

<160> 8     

<170> PatentIn version 3.5

<210> 1
<211> 381
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic antibody
      polynucleotide"

<400> 1
atgagtgtgc ccactcaggt cctggggttg ctgctgctgt ggcttacagg tgccagatgt       60

gacatccaga tgactcagtc tccagcctcc ctatctgctt ctgtgggaga aactgtcacc      120

atcacatgtc gaacaagtga gaatatttac agttatttag catggtatca acagaaacag      180

ggaaaatctc ctcagctcct agtctataat gcaaaaacct tagcagatgg tgtgccatca      240

aggttcagtg gcagtggatc aggcacacag ttttctctga agatcaacag cctgcagcct      300

gaagattttg ggaattatta ctgtcaaaat cattatggaa taccatatcc attcggatcg      360

gggaccaggc tggaaataaa a                                                381


<210> 2
<211> 417
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic antibody
      polynucleotide"

<400> 2
atgggatgga gctatatcat cctctttttg gtagcaacaa ctgcagatgt ccactcccag       60

gtccaactgc agcagcctgg ggctgaactg gtgaagcctg gggcttcagt gaatctgtcc      120

tgcaaggctt ctggctacac cttcaccagg tactggatac actgggtgaa gcagaggcct      180

ggacaaggcc ttgaatggat tggagagatt aatcctagca acggtcgtac taattacaat      240

gagaagttca agaccaaggc cacactgact gtagacaaat cctccaatac agcctacatg      300

caactcagca ggctgacatc tgaggactct gcggtctatt actgtgcaag agaaattgcc      360

tactatgatt acgacggtga ctactggggc caaggcacca ctctcacagt ctcctca         417


<210> 3
<211> 127
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic antibody
      polypeptide"

<400> 3
Met Ser Val Pro Thr Gln Val Leu Gly Leu Leu Leu Leu Trp Leu Thr 
1               5                   10                  15      


Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser 
            20                  25                  30          


Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Thr Ser Glu Asn 
        35                  40                  45              


Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro 
    50                  55                  60                  


Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser 
65                  70                  75                  80  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn 
                85                  90                  95      


Ser Leu Gln Pro Glu Asp Phe Gly Asn Tyr Tyr Cys Gln Asn His Tyr 
            100                 105                 110         


Gly Ile Pro Tyr Pro Phe Gly Ser Gly Thr Arg Leu Glu Ile Lys 
        115                 120                 125         


<210> 4
<211> 139
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic antibody
      polypeptide"

<400> 4
Met Gly Trp Ser Tyr Ile Ile Leu Phe Leu Val Ala Thr Thr Ala Asp 
1               5                   10                  15      


Val His Ser Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys 
            20                  25                  30          


Pro Gly Ala Ser Val Asn Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe 
        35                  40                  45              


Thr Arg Tyr Trp Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu 
    50                  55                  60                  


Glu Trp Ile Gly Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn 
65                  70                  75                  80  


Glu Lys Phe Lys Thr Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn 
                85                  90                  95      


Thr Ala Tyr Met Gln Leu Ser Arg Leu Thr Ser Glu Asp Ser Ala Val 
            100                 105                 110         


Tyr Tyr Cys Ala Arg Glu Ile Ala Tyr Tyr Asp Tyr Asp Gly Asp Tyr 
        115                 120                 125             


Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser 
    130                 135                 


<210> 5
<211> 381
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic antibody
      polynucleotide"

<400> 5
atgagtgtgc ccactcaggt cctggggttg ctgctgctgt ggcttacagg tgccagatgt       60

gacatccaga tgactcagtc tccagcctcc ctatgtgcat ctgtgggaga gactgtcacc      120

atcacatgtc gagcaagtga gaatatttac agttatttag catggtttca acagaaacag      180

ggaaaatctc ctcagctcct ggtctataat gcaaaaacct tggcagaagg tgtgccatca      240

aggttcagtg gcagtggatc aggcacacag ttttctctga ggatcaataa tatgcagcct      300

gaagattttg ggagttatta ctgtcaaaat cattataata atccgtatgc gttcggatcg      360

gggaccagtc tggaaataaa a                                                381


<210> 6
<211> 417
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic antibody
      polynucleotide"

<400> 6
atgggatgga gctatatcat cctcttttta gtagcaacag ctacagatgt ccactcccag       60

gtccaactgc accagcctgg ggctgaactg gtgaagcctg gggcttcagt gaagctgtcc      120

tgcaaggctt ctggctacac ctttaccaac tacgggatac actgggtgaa acagaggcct      180

ggacaaggcc ttgagtggat tggagagatt aatcctacca acggtcgtac taactacaat      240

gagaagttca agagcaaggc cacactgact gtcgacaaat cctccagcac agcctacatg      300

gaactcagca gcctgacatc tgaggactct gcggtctatt actgtgcaag atcctataat      360

tactatagtt acgacggaga cttctggggc caaggcacca ctctcacagt ctcctca         417


<210> 7
<211> 127
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic antibody
      polypeptide"

<400> 7
Met Ser Val Pro Thr Gln Val Leu Gly Leu Leu Leu Leu Trp Leu Thr 
1               5                   10                  15      


Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Cys 
            20                  25                  30          


Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn 
        35                  40                  45              


Ile Tyr Ser Tyr Leu Ala Trp Phe Gln Gln Lys Gln Gly Lys Ser Pro 
    50                  55                  60                  


Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser 
65                  70                  75                  80  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Arg Ile Asn 
                85                  90                  95      


Asn Met Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln Asn His Tyr 
            100                 105                 110         


Asn Asn Pro Tyr Ala Phe Gly Ser Gly Thr Ser Leu Glu Ile Lys 
        115                 120                 125         


<210> 8
<211> 139
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic antibody
      polypeptide"

<400> 8
Met Gly Trp Ser Tyr Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Asp 
1               5                   10                  15      


Val His Ser Gln Val Gln Leu His Gln Pro Gly Ala Glu Leu Val Lys 
            20                  25                  30          


Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe 
        35                  40                  45              


Thr Asn Tyr Gly Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu 
    50                  55                  60                  


Glu Trp Ile Gly Glu Ile Asn Pro Thr Asn Gly Arg Thr Asn Tyr Asn 
65                  70                  75                  80  


Glu Lys Phe Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser 
                85                  90                  95      


Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 
            100                 105                 110         


Tyr Tyr Cys Ala Arg Ser Tyr Asn Tyr Tyr Ser Tyr Asp Gly Asp Phe 
        115                 120                 125             


Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser 
    130                 135                 


